133 -5 (55) 2023 — Musashaykhov U.Х., Boboev K.T. — MOLECULAR-GENETIC ASPECTS OF THE RISK OF DEVELOPING METABOLIC SYNDROME

MOLECULAR-GENETIC ASPECTS OF THE RISK OF DEVELOPING METABOLIC SYNDROME

Musashaykhov U.Х., Andijan State Medical Institute

Boboev K.T., Republican Specialized Scientific and Practical Medical Hematology Center

Musashaykhova Sh.M., Andijan State Medical Institute

Teshaboyev M.G. Andijan State Medical Institute

Resume

In the course of the study, the peripheral blood of 64 patients with MS+MI and 58 patients with MI without MS who were treated with AF RSNPMC of the Ministry of Health of the Republic of Uzbekistan was used as a material for molecular genetic research. Molecular genetic studies were carried out in the Department of Molecular Medicine and Cellular Technologies of the RSNPMC of Hematology of the Republic of Uzbekistan.  The control group consisted of 155 “healthy” individuals with MS and MI at the moment and in anamnesis.  Molecular genetic studies were carried out in the Department of Molecular Medicine and Cellular Technologies of the RSNPMC of Hematology of the Republic of Uzbekistan. Amplification of DNA sections was carried out using polymerase chain reaction (PCR) in real time using TaqMan probes. Statistical processing of the results was performed using the standard OpenEpi V.9.2 application software package.

Keywords: metabolic syndrome, myocardial infarction, diabetes mellitus, dyslipidemia, genotype, genetic polymorphism of Pro12Ala in the PPARG2 gene.

First page

758

Last page

761

For citation: Musashaykhov U.Х., Boboev K.T., Musashaykhova Sh.M., Teshaboyev M.G. – MOLECULAR-GENETIC ASPECTS OF THE RISK OF DEVELOPING METABOLIC SYNDROME //New Day in Medicine 2023 5(55): 758-761 https://newdaymedicine.com/index.php/2023/07/01/l-243/

LIST OF REFERENCES:

1. Bovolini António et al. “Metabolic Syndrome Pathophysiology and Predisposing Factors.” International journal of sports medicine vol. 42,3 (2021): 199-214. doi:10.1055/a-1263-0898.
2. McCracken Emma et al. “Pathophysiology of the metabolic syndrome.” Clinics in dermatology vol. 36,1 (2018): 14-20. doi:10.1016/j.clindermatol.2017.09.004
3. Saklayen Mohammad G. “The Global Epidemic of the Metabolic Syndrome.” Current hypertension reports vol. 20,2 12. 26 Feb. 2018, doi:10.1007/s11906-018-0812-z.
4. Jenča Dominik et al. “Heart failure after myocardial infarction: incidence and predictors.” ESC heart failure vol. 8,1 (2021): 222-237. doi:10.1002/ehf2.13144
5. Sherling Dawn Harris et al. “Metabolic Syndrome.” Journal of cardiovascular pharmacology and therapeutics vol. 22,4 (2017): 365-367. doi:10.1177/1074248416686187
6.  Silveira Rossi, João Leonardo et al. “Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors.” Diabetes/metabolism research and reviews vol. 38,3 (2022): e3502. doi:10.1002/dmrr.3502.
7. Cho Young-Hye et al. “Biomarkers in metabolic syndrome.” Advances in clinical chemistry vol. 111 (2022): 101-156. doi:10.1016/bs.acc.2022.07.003
8. Son Da-Hye et al. “New markers in metabolic syndrome.” Advances in clinical chemistry vol. 110 (2022): 37-71. doi:10.1016/bs.acc.2022.06.002
9. Godfrey Timian M et al. “Metabolic Syndrome Among American Indian and Alaska Native Populations: Implications for Cardiovascular Health.” Current hypertension reports vol. 24,5 (2022): 107-114. doi:10.1007/s11906-022-01178-5
10. Rochlani Yogita et al. “Metabolic syndrome: pathophysiology, management, and modulation by natural compounds.” Therapeutic advances in cardiovascular disease vol. 11,8 (2017): 215-225. doi:10.1177/1753944717711379.